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Abstract
Aim: The effects of 24(S),25-epoxycholesterol (24,25EC) on aspects of cholesterol homeostasis is well-
documented. When added to cells, 24,25EC decreases cholesterol synthesis and up-regulates cholesterol
efflux genes, including ABCA1. Synthesis of 24,25EC occurs in a shunt of the mevalonate pathway which
also produces cholesterol. Therefore, 24,25EC synthesis should be subject to the same negative feedback
regulation as cholesterol synthesis. To date, no role has been ascribed to 24,25EC in light of the fact that
increased accumulation of cholesterol should decrease formation of this oxysterol through feedback
inhibition. This leads to the intriguing paradox: why inhibit production of an apparently important regulator
of cholesterol homeostasis when it is needed most?
Methods: We used a combination of pharmacological and genetic approaches in Chinese Hamster Ovary
cell-lines to investigate this paradox. Endogenous synthesis of 24,25EC was manipulated using partial
inhibition of the enzyme, Oxidosqualene Cyclase. Changes in cholesterol and 24,25EC synthesis were
determined using metabolic labelling with [1-14C]-acetate, thin-layer chromatography and
phosphorimaging. Transcriptional effects mediated via SREBP and LXR were analysed by luciferase
reporter assays.
Results: We showed that cholesterol addition to cells lead to a rapid and preferential inhibition of
24,25EC synthesis. Addition of 24,25EC resulted in parallel inhibition of 24,25EC and cholesterol synthesis.
Furthermore, we used a variety of approaches to examine the relationship between cholesterol and
24,25EC synthesis, including cell-lines with different rates of cholesterol synthesis, varying cholesterol
synthetic rates by pre-treatment with a statin, or lipoprotein cholesterol loading of macrophages. In all
cases, we showed that 24,25EC synthesis faithfully tracked cholesterol synthesis. Moreover, changes in
24,25EC synthesis exerted downstream effects, reducing SREBP transcriptional activity whilst increasing
ABCA1 and LXR transcriptional activity.
Conclusion: Our results show that 24,25EC synthesis parallels cholesterol synthesis, consistent with this
oxysterol functioning as a safety valve to protect against the accumulation of newly-synthesised cholesterol
(as opposed to exogenously-derived cholesterol). Considering that 24,25EC is capable of being produced
in all cholesterogenic cells, we propose that production of 24,25EC may represent a ubiquitous defence
mechanism.
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Background
Oxygenated cholesterol derivatives or oxysterols are
potential regulatory molecules in cholesterol homeosta-
sis. The regulatory effect of oxysterols was first identified
by Kandutsch and colleagues [1] who showed that the
suppressive effect of cholesterol on its own synthesis may
be mediated by endogenously-produced oxysterols. This
became known as the "Oxysterol Hypothesis of Choles-
terol Homeostasis" [1].
Certain oxysterols can act as suppressors of 3-hydroxy-3-
methylglutaryl (HMG)-CoA reductase, the rate-limiting
enzyme in the mevalonate pathway which also synthe-
sises cholesterol [2]. It has been demonstrated that oxys-
terols decrease the expression of cholesterol synthetic and
uptake genes by suppressing sterol regulatory element-
binding protein-2 (SREBP-2) mediated transcription
[3,4]. Moreover, certain oxysterols can act as ligands for
the Liver × Receptor (LXR), which mediates transcription
of cholesterol export genes, such as the ATP-binding cas-
sette transporter, ABCA1 [5-7]. Most of the common phys-
iological oxysterols characterised (such as the
hydroxycholesterols) are derived from enzymatic oxida-
tion of cholesterol, either from circulating lipoproteins or
from synthesised cholesterol [8,9].
The oxysterol 24(S),25-epoxycholesterol (24,25EC) is
unique in that it is not derived from cholesterol. Instead,
24,25EC is produced de novo in the mevalonate pathway
which simultaneously synthesizes cholesterol. 24,25EC
was first characterised by Nelson, Steckbeck and Spencer
[10] who showed that 24,25EC was derived from acetyl
CoA via a shunt in the mevalonate pathway. Since then,
exogenous addition of 24,25EC has been shown in vitro to
decrease HMG-CoA reductase activity [11], to suppress
SREBP processing [4], and to potently activate LXR-gene
targets [6,7,12]. We have previously shown that statins
inhibit the production of 24,25EC in human macro-
phages under basal conditions leading to decreases in LXR
target gene expression including ABCA1 and ABCG1 [13].
Moreover, beneficial effects on cholesterol homeostasis
have been reported in vitro [13-17] and in vivo [18-21]
when endogenous synthesis of 24,25EC is stimulated.
Two recent reviews [22,23], have highlighted the interest
in 24,25EC as a central regulator of cholesterol homeosta-
sis [22].
Feedback regulation of cholesterol synthesis is well estab-
lished [2]. When cholesterol levels in the cell are high,
SREBP-processing is inhibited resulting in down-regula-
tion of SREBP-target genes, including HMG-CoA reduct-
ase [2]. Considering that cholesterol and 24,25EC
synthesis utilize the same enzymes and cofactors, synthe-
sis of 24,25EC would be expected to decrease when cellu-
lar cholesterol accumulates and feeds back on the
mevalonate pathway. This leads to the intriguing ques-
tion: why inhibit production of a compound that potently
regulates cholesterol homeostasis when it is needed most?
To date, no publication on 24,25EC has addressed or even
raised this important issue. Our current work helps to
resolve this paradox by showing that although cholesterol
addition potently inhibits 24,25EC synthesis, synthesis of
this oxysterol tends to track cholesterol synthesis under a
variety circumstances. This has lead us to propose that
production of this oxysterol represents a ubiquitous
defence mechanism against cellular accumulation of cho-
lesterol that is newly-synthesised in the mevalonate path-
way (as opposed to exogenously-derived cholesterol).
Results
Cholesterol accumulation inhibits 24(S),25-
epoxycholesterol synthesis
Considering that both 24,25EC and cholesterol are syn-
thesised in the mevalonate pathway, we would predict
that 24,25EC synthesis should also be decreased upon cel-
lular cholesterol accumulation as a consequence of feed-
back inhibition of the mevalonate pathway. To test this,
we utilised Chinese Hamster Ovary (CHO) cells, a cell-
line commonly-used to study cholesterol homeostasis
that has been instrumental in the identification of many
of the major components of the cholesterol homeostatic
machinery [24]. CHO-7 cells were cholesterol-loaded by
incubation with incremental concentrations of choles-
terol complexed to methyl-β-cyclodextrin in the presence
of [1-14C]-acetate. Non-saponifiable lipids were extracted,
separated by thin layer chromatography and phosphorim-
aged. Quantification of cholesterol and 24,25EC by den-
sitometry of the phosphorimage or by scintillation
counting yielded linear responses in the standard curve
for both sterols (Additional file 1). Thus, changes in cho-
lesterol and 24,25EC synthesis were subsequently quanti-
fied by densitometry of the phosphorimage. Cholesterol-
loading decreased synthesis of both sterols as predicted.
However, 24,25EC synthesis appeared to decrease prefer-
entially (Fig. 1A, C). Incubation of CHO-7 cells with
24,25EC was more potent in inhibiting sterol synthesis
than cholesterol-loading (Fig. 1Dvs. 1C) and decreased
both cholesterol and 24,25EC synthesis to a similar extent
(Fig. 1B, D).
The effects of added cholesterol or 24,25EC on sterol syn-
thesis were then examined over time (Fig. 1E, F). Choles-
terol-loading and 24,25EC incubation decreased the
synthesis of the two sterols within hours of treatment. The
preferential decrease in 24,25EC synthesis in response to
cholesterol-loading was evident within the first two hours
(Fig. 1E).
Therefore, 24,25EC synthesis is inhibited in response to
added sterols. We postulate that 24,25EC may be func-Lipids in Health and Disease 2007, 6:10 http://www.lipidworld.com/content/6/1/10
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Exogenously-added sterols feed back on cholesterol and 24,25EC synthesis Figure 1
Exogenously-added sterols feed back on cholesterol and 24,25EC synthesis. CHO-7 cells were incubated with either 
increasing concentrations (A) or 50 μM (E) of cholesterol complexed to methyl-β-cyclodextrin; or either increasing concen-
trations (B) or 10 μM (F) of 24,25EC in the presence of [1-14C]-acetate for 24 h or (E, F) labelled 2 h before the indicated 
time of harvest. Neutral lipid extracts were separated by thin-layer chromatography and bands corresponding to authentic 
cholesterol and 24,25EC were visualized by phosphorimager. These phosphorimages are representative of 2 separate experi-
ments. Bands corresponding to cholesterol and 24,25EC were quantified by densitometry. For (C, D) data sets from 2 (C) or 
3 (D) separate experiments represented by Figure 1A and Figure 1B were pooled. Equation for the lines of best fit (C) choles-
terol (solid diamond; solid line) y = -1.35x + 84.79; R2 = 0.75; P < 0.01; (D) 24,25EC (empty square; dashed line) y = -5.68x + 
76; R2 = 0.58; P < 0.01; cholesterol (solid diamond; solid line) y = -5.96x + 78; R2= 0.63; P < 0.01. For (E, F) data sets are rep-
resentativeof n = 2 separate experiments.Lipids in Health and Disease 2007, 6:10 http://www.lipidworld.com/content/6/1/10
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tioning to protect against intracellular accumulation of
cholesterol when its synthesis in the mevalonate pathway
is active.
Synthesis of 24(S),25-epoxycholesterol faithfully tracks 
cholesterol synthesis
If 24,25EC protects against newly-synthesised cholesterol,
we would predict that syntheses of these two sterols
should correlate. This was observed when addition of
24,25EC decreased synthesis of 24,25EC and cholesterol
in parallel (Fig. 1D, F). We investigated this further using
a variety of Chinese Hamster Ovary cell-lines containing
specific mutations in the SREBP-processing pathway
which lead to altered cholesterol biosynthesis rates
(details presented in [25]). Regardless of the mutation,
synthesis of 24,25EC was correlated with cholesterol syn-
thesis (Fig. 2A, B).
In another experimental approach, the rate of cholesterol
synthesis was varied in CHO-7 cells by pre-incubating
with increasing concentrations of the archetypal statin,
compactin. Statins decrease cholesterol synthesis by
inhibiting HMG-CoA reductase (Fig. 3A). The resulting
cholesterol depletion induces SREBP activation [26] and
consequently up-regulates expression of key rate-limiting
cholesterol biosynthetic enzymes, including HMG-CoA
reductase [13,25] (Fig. 3B). Hence, after pre-incubation
when compactin is removed, there is an increase in the
rate of cholesterol synthesis in the mevalonate pathway
(Fig. 3C). The induction in cholesterol synthesis increased
by up to four-fold and yet again was closely tracked by
24,25EC synthesis (Fig. 3D).
In our final approach, we studied the effects of lipoprotein
cholesterol loading on cholesterol and 24,25EC synthesis
in macrophages, a cell-type particularly relevant to the eti-
ology of atherosclerosis. For these experiments, we uti-
lized the human macrophage-like cell-line, THP-1 [13].
Cholesterol loading of THP-1 human macrophages with
acetylated LDL decreased both cholesterol and 24,25EC
synthesis in unison (Fig. 4A, B).
Taken together, these positive correlations between cho-
lesterol and 24,25EC synthesis and the potent suppressive
effect of added 24,25EC on cholesterol synthesis (Fig. 1B,
1D) support its role as a feedback regulator when choles-
terol is being actively synthesised.
24(S),25-epoxycholesterol regulates SREBP- and LXR-
mediated transcription
Addition of certain oxysterols including 24,25EC, are
known to block SREBP-2 activation in the cell [3,4]. To
assess changes in gene transcription, we employed luci-
ferase reporter constructs containing tandem repeats of
the motif at which transcriptional changes take place. The
effect of added 24,25EC on SREBP-mediated transcription
was examined using a luciferase reporter construct con-
taining 6 tandem copies of the classical sterol response
element from the promoter of the LDL receptor, ATCAC-
CCCAC (SRE-luc) [27,28]. Hence, changes in SRE-luc
reporter activity reflect SREBP-mediated transcription.
24,25EC is a potent activator of LXR-target genes [6,12]
including the cholesterol efflux gene, ABCA1 [29,30]. To
assess LXR-mediated gene transcription, we used a luci-
ferase reporter construct containing a 1 kb fragment of the
human ABCA1 promoter [30] as well as a luciferase
reporter containing 3 repeats of the minimal DR4 motif
(LXRE-luc). In agreement with our previous findings [25],
addition of increasing concentrations of 24,25EC lead to
a decrease in SRE reporter activity and to reciprocal
Endogenously-produced 24,25EC correlates with cholesterol  synthesis in different CHO cell-lines Figure 2
Endogenously-produced 24,25EC correlates with 
cholesterol synthesis in different CHO cell-lines. (A) 
Various Chinese Hamster Ovary cell-types with different 
abilities to synthesise cholesterol were incubated in the pres-
ence of [1-14C]-acetate for 24 h. KEY: 1. CHO-7; 2. SRD-1; 
3. M19; 4. SRD-13A; 5. 13A/pSCAP. For more details about 
these cell-lines, see [25]. Neutral lipid extracts were sepa-
rated by thin-layer chromatography and bands corresponding 
to authentic cholesterol and 24,25EC were visualized by 
phosphorimager and quantified by densitometry. Equations 
for the lines of best fit (B) y = 0.97x + 0.39; R2 = 0.89; P < 
0.03. Values are means from 3 separate experiments set rela-
tive to CHO-7 cells which was assigned an arbitrary value of 
1.Lipids in Health and Disease 2007, 6:10 http://www.lipidworld.com/content/6/1/10
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increases in ABCA1 and LXRE-luc reporter activity (Fig.
5A–C)).
It is well documented that addition of 24,25EC has
marked effects on parameters associated with cholesterol
homeostasis [6,13,14,25]. We aimed to determine if
endogenous 24,25EC also has the expected effects on
SREBP- and LXR- mediated transcription. A specific inhib-
itor of the enzyme 2,3-oxidosqualene cyclase (OSC),
GW534511X, was used to partially inhibit the activity of
this enzyme, hence increasing the amount of 24,25EC
produced in the shunt pathway (illustrated in Fig. 6A, B).
We and others have shown that use of high OSC inhibitor
concentrations increase production of 2,3(S):22(S),23-
dioxidosqualene (DOS) and almost completely abolish
cholesterol synthesis [13,14,17]. Since these may produce
confounding effects, lower inhibitor concentrations were
used. In agreement with previous studies [13-16,18,20],
we found that partial OSC inhibition increased 24,25EC
synthesis and decreased cholesterol synthesis (Fig. 6C).
When endogenous 24,25EC synthesis was increased by
partial OSC inhibition (Fig. 6C), SREBP-reporter activity
was decreased (Fig. 6D). In addition, we assessed SREBP-
processing through use of an SREBP-reporter fusion con-
struct [26] which confirmed that endogenously-produced
24,25EC decreased SREBP-processing (data not shown).
ABCA1 luciferase reporter activity increased in accordance
with the increase in 24,25EC synthesis when OSC was
partially inhibited by 0.1 nM and 1 nM GW534511X (Fig.
6E). To confirm that ABCA1 promoter activity was indeed
Endogenously-produced 24,25EC correlates with cholesterol synthesis when cholesterol synthesis is stimulated by statin-pre- treatment Figure 3
Endogenously-produced 24,25EC correlates with cholesterol synthesis when cholesterol synthesis is stimu-
lated by statin-pre-treatment. (A) CHO-7 cells were incubated with the indicated concentrations of compactin in the 
presence of [1-14C]-acetate for 24 h. Neutral lipid extracts were separated by thin-layer chromatography and bands corre-
sponding to authentic cholesterol and 24,25EC were visualized by phosphorimager and quantified by densitometry. Values are 
means+SEM from 3 separate experiments. (B, C) CHO-7 cells were pre-incubated with the indicated concentrations of com-
pactin for 24 h. (B) mRNA levels for HMG-CoA reductase was measured using QRT-PCR. Data are presented relative to vehi-
cle-treated controls and are means+SEM (3 replicate cultures representative of 2 separate experiments). (C) Cells were then 
incubated in the presence of [1-14C]-acetate for 2 h. Neutral lipid extracts were separated by thin-layer chromatography and 
bands corresponding to authentic cholesterol and 24,25EC were visualized by phosphorimager and quantified by densitometry. 
Equations for the lines of best fit (D) y = 1.47x - 0.42; R2 = 0.99; P < 0.001. Values are means from 2 separate experiments set 
relative to the vehicle-treated control condition which was assigned an arbitrary value of 1.Lipids in Health and Disease 2007, 6:10 http://www.lipidworld.com/content/6/1/10
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the result of increased endogenous synthesis of LXR lig-
and 24,25EC, two approaches were employed. Firstly, the
wild-type ABCA1 reporter construct was mutated at the
LXR response element, DR4 motif (DR4 mutant).
Reporter activity of the DR4 mutant construct was lower
than that of the wild-type construct and displayed no
response to changes in endogenous 24,25EC synthesis
(Fig. 6E). Secondly, we observed similar effects of
GW534511X treatment on LXRE-luc activity as compared
with ABCA1 reporter activity (Fig. 6F). This confirms that
the changes induced by GW534511X were mediated
through the LXR response element and are most likely due
to endogenous 24,25EC synthesis. This result also sug-
gests that the effect of endogenously-produced 24,25EC
should be applicable to other LXR-target genes.
Collectively, our results support the idea that endog-
enously-produced 24,25EC may act as a feedback regula-
tor to protect the cell against the cholesterol accumulation
of newly-synthesized cholesterol.
Added 24(S),25-epoxycholesterol regulates SREBP- and  LXR-mediated transcription Figure 5
Added 24(S),25-epoxycholesterol regulates SREBP- 
and LXR-mediated transcription. (A-C) CHO-7 cells 
were transiently transfected for 24 h with phRL-TK Renilla 
internal control plasmid together with either (A) SRE-luc, 
(B) pGL3-hABCA1 wild-type, (C) LXRE-luc. Following trans-
fection, cells were incubated for 24 h in the absence or pres-
ence of indicated concentrations of 24,25EC. Data are 
presented as percentage change relative to the vehicle-
treated control condition. (A,B) Values are mean+SEM (n = 
3 separate experiments). (C) Values aremean+SEM (n = 3 
replicate cultures representative of 3 separate experiments).
Endogenously-produced 24,25EC correlates with cholesterol  synthesis when macrophages are cholesterol-loaded Figure 4
Endogenously-produced 24,25EC correlates with 
cholesterol synthesis when macrophages are choles-
terol-loaded. (A) THP-1 monocytes differentiated into 
macrophages for 3 d in 50 ng/μl of PMA. THP-1 macrophages 
were loaded with acetylated LDL for 24 h whilst labelling 
with [1-14C]-acetate. Neutral lipid extracts were separated 
by thin-layer chromatography and bands corresponding to 
authentic cholesterol and 24,25EC were visualized by phos-
phorimager and quantified by densitometry. Neutral lipid 
extracts were separated by thin-layer chromatography and 
bands corresponding to authentic cholesterol and 24,25EC 
were visualized by phosphorimager and quantified by densit-
ometry. Equations for the lines of best fit (B) y = 0.88x; R2 = 
0.97; P < 0.0001. Values are pooled from 2 separate experi-
ments set relative to the vehicle-treated control condition 
which was assigned an arbitrary value of 1.Lipids in Health and Disease 2007, 6:10 http://www.lipidworld.com/content/6/1/10
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Endogenous 24(S),25-epoxycholesterol regulates SREBP- and LXR-mediated transcription Figure 6
Endogenous 24(S),25-epoxycholesterol regulates SREBP- and LXR-mediated transcription. (A) Under normal 
conditions, cholesterol synthesis is favoured but some 24,25EC is still produced. (B) Since oxidosqualene cyclase (OSC) pref-
erentially cyclises 2,3(S):22(S),23-dioxidosqualene (DOS) over 2,3(S)-monooxidosqualene (MOS), partial inhibition of OSC 
favours synthesis of 24,25EC. (C) CHO-7 cells were incubated with increasing concentrations of GW534511X in the presence 
of [1-14C]-acetate for 24 h. Neutral lipid extracts were separated by thin-layer chromatography and bands corresponding to 
authentic cholesterol and 24,25EC were visualized by phosphorimager. This phosphorimage is representative of 3 separate 
experiments. (D-F) CHO-7 cells were transiently transfected for 24 h with phRL-TK Renilla internal control plasmid together 
with either (D) SRE-luc, (E) pGL3-hABCA1 wild-type or DR4 mutant, (F) LXRE-luc. Following transfection, cells were incu-
bated for 24 h in the absence or presence of indicated concentrations of GW534511X. Data are presented as percentage 
change relative to (E) the pGL3-hABCA1 wild-type construct vehicle-treated control condition or (D, F) vehicle-treated con-
trol condition. (D, E, F) are means+SEM(n = 3 separate experiments); for (E) DR4 mutant are means+halfrange (n = 2 sepa-
rate experiments).Lipids in Health and Disease 2007, 6:10 http://www.lipidworld.com/content/6/1/10
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Discussion
24,25EC, produced de novo in a shunt of the mevalonate
pathway, is a promising physiological oxysterol mediator
of cholesterol homeostasis [22,23]. The shunt pathway
runs parallel to cholesterol synthesis. Thus enzymes for
the synthesis of both cholesterol and 24,25EC are shared
and subject to the same regulation. Paradoxically, synthe-
sis of 24,25EC decreases when cholesterol accumulates
and feeds back, preventing activity of the mevalonate
pathway i.e. when cellular cholesterol is high and the
need for 24,25EC should be greatest. Our current work
helps to clarify this paradox by proposing a previously
unrecognized role of 24,25EC as a defence mechanism
against cellular accumulation of newly-synthesized cho-
lesterol as opposed to exogenously-derived cholesterol
from lipoproteins. Below we present several lines of evi-
dence in support of this contention.
Firstly, we showed that addition of pure cholesterol to
cells preferentially shut down synthesis of 24,25EC (Fig.
1C, E). Moreover, lipoprotein-cholesterol loading of mac-
rophages also decreased 24,25EC synthesis (Fig. 4A).
These results confirm our prediction that 24,25EC's role
can not be to protect against accumulation of exogenous
cholesterol and suggests a feed-back system designed to
preferentially attenuate levels of this oxysterol when cho-
lesterol synthesis is not required.
We further explored the role of 24,25EC synthesis as a
feed-back mechanism by employing four different experi-
mental approaches (Fig. 1B, Fig. 2B, 3D, 4B). We found
that synthesis of 24,25EC faithfully tracks cholesterol syn-
thesis in each case. Firstly, we suppressed the activity of
the mevalonate pathway by addition of exogenous
24,25EC. Both cholesterol and 24,25EC synthesis
decreased in unison and the effects observed were
dependent on concentration and time (Fig. 1D, F). Sec-
ondly, through the use of mutant CHO cell-lines which
exhibit varying rates of cholesterol synthesis, we found
that 24,25EC synthesis follows cholesterol synthesis (Fig.
2B). Thirdly, when the biosynthetic activity of the meval-
onate pathway was increased by statin-pre-treatment, we
also observed parallel increases in cholesterol and
24,25EC synthesis (Fig. 3D). Finally, cholesterol-loading
of the human macrophage cell-line, THP-1, produced par-
allel decreases in cholesterol and 24,25EC synthesis (Fig.
4B).
We also showed that synthesised 24,25EC had the
expected downstream effects on LXR- and SREBP-medi-
ated gene transcription. Induction of endogenous
24,25EC synthesis with the OSC inhibitor GW534511X
activated ABCA1 transcription (Fig. 6E) in agreement with
previous studies which have reported increased ABCA1
mRNA levels in response to partial inhibition of OSC
[13,14,17]. The reciprocal effects were observed for
SREBP-mediated gene transcription (Fig. 6D) which
decreased as 24,25EC synthesis increased. Again, this is in
keeping with previous studies [4,14]. The magnitude of
effects observed in these luciferase reporter assays is simi-
lar to those observed in response to sub-micromolar con-
centrations of added 24,25EC (Fig. 5).
Together, the parallel relationships observed between
24,25EC and cholesterol synthesis as well as the down-
steam effects of increased 24,25EC synthesis can be
rationalized if 24,25EC represents 'a safety-valve' for pro-
tecting against the accumulation of newly-synthesized
cholesterol (Fig. 7). Where precursors of cholesterol syn-
thesis diverge to form 24,25EC, this oxysterol can then be
utilised as a regulatory molecule to decrease cholesterol
synthesis, inhibit SREBP-2 mediated transcription, and to
upregulate cholesterol efflux processes.
As both 24,25EC and cholesterol are synthesised in the
mevalonate pathway, any cell that can synthesize choles-
terol also has the capacity to generate 24,25EC. So far, sev-
eral cell-types have been shown to generate 24,25EC
(including hepatocytes [15,17] (Additional file 2), macro-
phages [13,14] (Fig. 4A), fibroblasts and lung cells [31]).
Spencer et al. [32] previously estimated that the human
liver contains 10–30 μM of 24,25EC. At this concentra-
tion range the activity HMG-CoA reductase could be sup-
pressed by 50% in fibroblast cell culture [32].
The evidence presented herein is, of necessity, correla-
tional. The use of genetic manipulation to test the idea
that 24,25EC may represent a ubiquitous defence mecha-
nism against newly-synthesized cholesterol is problem-
atic, since synthesis of cholesterol and 24,25EC occur
concurrently using the same enzymes. However, some in
vivo evidence for this hypothesis was provided by Zhang et
al. [19], who found that 24,25EC was relatively enriched
in the nuclear fraction of rat liver homogenates, placing it
in the correct location to act as an in vivo LXR ligand. Fur-
thermore, 1 h after administering a bolus of mevalonic
acid to rats, hepatic levels of 24,25EC doubled, in contrast
to the other oxysterols measured. These observations are
consistent with 24,25EC being produced in response to an
overactive mevalonate pathway and supports the hypo-
thesis that it can protect the cell from accumulation of
newly-synthesized cholesterol.
Previously, we speculated that human macrophages may
produce ligands for LXR, depending on the supply of
exogenous cholesterol versus the activity of the shunt
pathway [13]. When cholesterol status is sufficient, feed-
back inhibition of the mevalonate pathway occurs and
enzymatic conversion of cholesterol to oxysterols may be
the dominant mechanism for up-regulating cholesterolLipids in Health and Disease 2007, 6:10 http://www.lipidworld.com/content/6/1/10
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efflux genes like ABCA1, overriding any effects of
24,25EC. Indeed, when THP-1 macrophages were loaded
with acetylated LDL, we observed corresponding
decreases in cholesterol and 24,25EC synthesis (Fig. 4A).
However, the conversion of cholesterol to oxysterols will
be cell-type specific, for example, another LXR ligand
24(S)-hydroxycholesterol, is synthesized exclusively in
the brain and thus probably does not function as a regu-
latory molecule in other cell-types [8]. In cells capable of
synthesizing oxysterols from cholesterol, we propose that
24,25EC may serve as an auxiliary mechanism for when
cholesterol synthesis is high. In cell-types unable to con-
vert cholesterol into oxysterol ligands, we propose that
24,25EC may play a greater role in regulating cholesterol
homeostasis.
In summary, this is the first study to rationalize the pro-
duction of 24,25EC as a ubiquitous defence mechanism
against newly-synthesized cholesterol. Given the role of
24,25EC in cholesterol homeostasis and the importance
of OSC in determining its endogenous production, it is
not surprising that this enzyme is of considerable interest
as a pharmacological target [14,17,22,23]. Funk and
Landes [33] reported that treatment of hamsters and dogs
with OSC inhibitors produced various histopathological
lesions, including early-stage cataracts. However, these
authors concluded that all adverse effects described were
exaggerated at the high dosage levels employed and sug-
gested that use of lower doses of hepatosensitive OSC
inhibitors should reduce the probability of adverse side-
effects in humans [33]. Instead of blocking the entire
mevalonate pathway with statins, the idea of manipulat-
ing a pre-existing and self-regulating pathway for the pro-
duction of a physiological oxysterol mediator, that can
augment cholesterol removal and decrease uptake and
synthesis, is attractive and warrants further evaluation.
Methods
Materials
Chemicals and reagents used are listed below with the
supplier. From GE Healthcare (formerly Amersham Bio-
sciences): [1-14C]-acetic acid, sodium salt (specific activ-
ity: 56 mCi/mmol). From Invitrogen: Dulbecco's
modified Eagle's medium/Ham's F-12 medium (50/50
mixture); RPMI 1640; L-glutamine; Lipofectamine 2000;
new born calf serum; fetal calf serum; penicillin/strepto-
A working hypothesis showing 24,25EC's role in protecting against accumulation of newly-synthesised cholesterol Figure 7
A working hypothesis showing 24,25EC's role in protecting against accumulation of newly-synthesised choles-
terol. Synthesis of cholesterol is accompanied by synthesis of 24,25EC in the same pathway. 24,25EC can inhibit cholesterol 
uptake and synthesis by suppressing SREBP activation. 24,25EC can also promote cholesterol efflux by serving as a ligand for 
LXR target genes, including ABCA1.Lipids in Health and Disease 2007, 6:10 http://www.lipidworld.com/content/6/1/10
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mycin. From Promega: phRL-TK Renilla plasmid. From
Sigma: compactin (also called mevastatin); phorbol 12-
myristate 13-acetate (PMA); TriReagent; oligonucleotides
were synthesized by Sigma-Genosys. From Steraloids:
cholesterol; 24(S),25-epoxycholesterol. Other reagents
were: analytical- or HPLC-grade solvents (EM Science);
UltimaGold scintillation fluid (Packard Bioscience). Lipo-
protein-deficient serum (LPDS) was prepared from new
born calf serum or human serum [34]. Acetylation of low
density lipoprotein (LDL) to acetylated LDL was prepared
as previously described [35]. Chinese Hamster Ovary cell-
lines, were generously provided by Drs. Michael S. Brown
and Joseph L. Goldstein (UT Southwestern, Dallas). A
reporter construct (pGL3-hABCA1) containing a fragment
of the human ABCA1 promoter (-928 bp to +101 bp) was
a kind gift from Dr Alan Tall (Columbia University, New
York). Another reporter construct (pGL3-TK) was donated
by Dr Malcolm Lyons (Western Australian Institute of
Medical Research). The 2,3-oxidosqualene cyclase (OSC)
inhibitor, GW534511X, was kindly provided by Glaxo
Smith-Kline.
Cell Culture
All cell types used were grown at 37°C in a 5% CO2
atmosphere. CHO-7 cells were cultured in Dulbecco's
modified Eagle's medium/Ham's F-12 medium (1:1 mix-
ture). These and other Chinese Hamster Ovary cell-lines
were maintained as described [25]. THP-1 human mono-
cytes were cultured in RPMI 1640 plus 10% (v/v) FCS sup-
plemented with penicillin/streptomycin 100 U/100 μg/
ml and L-glutamine (2 mM). Differentiation into macro-
phages was achieved by addition of PMA (50 ng/μl) for
three days. Treatments were conducted for 24 h in media
containing 5% (v/v) LPDS. All treatments were added to
cells either in absolute ethanol, dimethyl sulfoxide or
water and compared with vehicle-only controls. No cell-
toxicity was observed for any treatment at the concentra-
tions employed.
Cholesterol and 24(S),25-Epoxycholesterol synthesis assay
Cells were metabolically labelled with [1-14C]-acetic acid
for 2 or 24 h during treatments as previously described
[13]. THP-1 macrophages were loaded with acetylated
LDL whilst labelling with [1-14C]-acetic acid for 24 h.
Cells were harvested and cell protein was determined by
the bicinchoninic acid assay (Pierce). Samples were
saponified and standardised for equal protein loading
(~150 μg protein) and neutral lipid extracts were sepa-
rated by thin-layer chromatography. Bands corresponding
to authentic cholesterol and 24,25EC were visualized
using the FLA-5100 phosphoimager (Fujifilm, Tokyo,
Japan) (18–72 h exposure). Quantification of bands by
densitometry was conducted with Sciencelab ImageGauge
4.0 Software (Fujifilm). Positive identification of the band
corresponding to 24,25EC has previously been performed
chemically and by mass spectrometry (see supplemental
data of reference [13]). To validate our results based on
densitometry of the phosphorimage, we also performed
scintillation counting for an experiment that established
linearity of responses (Additional file 1). We show that
increasing levels of [14C]-cholesterol and [14C]-24,25EC
give proportional increases in response using both meth-
ods of quantification. Following thin layer chromatogra-
phy, bands corresponding to authentic cholesterol and
24,25EC were cut and eluted with methanol:peroxide free
diethyl ether (1:1) v/v. Radioactivity was determined by
scintillation counting (Packard Tri-Carb 2100 TR Liquid
Scintillation Analyzer) using UltimaGold scintillation
fluid (5 ml).
Plasmid constructs
Mutations in the LXR response element (DR4 motif) in a
fragment of the hABCA1 promoter that is linked to the
firefly luciferase reporter gene [30] was generated using
the Quickchange site-directed mutagenesis kit (Strata-
gene) [25] and sequences were verified. The 6 × SRE-luci-
ferase reporter has been previously described [25]. A 3 ×
LXRE-luciferase reporter (LXRE-luc) was constructed
using a similar approach [25]. Briefly, the 3 × LXRE-luc
insert was constructed by annealing complementary
sequences of a 3 × repeat containing the DR4 motif
(underlined) "tgaatgaccagcagtaacctcagc" [36]; and KpnI
and XhoI restriction sites synthesized at the 5' and 3' ends
respectively (Sigma-Genosys). The annealed insert and a
pGL3-TK vector were then sequentially digested with their
respective restriction enzymes and both digested insert
and vector were then ligated with T4 DNA ligase and
transformed into the DH5α E. coli strain. Positive clones
were verified by sequencing.
Human ABCA1 promoter activity assay
Promoter analysis was performed as previously described
[25]. Briefly, reporter plasmids (250 ng/well) were trans-
fected for 24 h into cells using Lipofectamine 2000 (1 μl/
well). The phRL-TK Renilla internal control plasmid (25
ng/well) was co-transfected for normalization of transfec-
tion efficiency. After treatment (24 h), cells were washed
and resuspended in 100 μl of 1 × passive lysis buffer
(Promega). Luciferase assays were performed using the
Dual Luciferase Assay Reporter System according to the
manufacturer's instructions in a Veritas luminometer
(Turner Designs). Results were expressed as changes in
luciferase activity relative to vehicle-treated controls or the
wild-type ABCA1 vehicle-treated control condition.
Reverse Transcriptase PCR and Quantitative Real-time 
PCR
Cells were harvested for total RNA using Tri Reagent
according to the manufacturer's instructions. Concentra-
tions of total RNA were measured by spectrophotometryLipids in Health and Disease 2007, 6:10 http://www.lipidworld.com/content/6/1/10
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(Nanodrop ND-100 Spectrophotometer, Biolab). Reverse
Transcriptase-PCR was performed according to the manu-
facturer's protocol for SuperScript III First Strand cDNA
Synthesis Kit (Invitrogen). Quantitative ('real-time')
Reverse Transcriptase-PCR (QRT-PCR) was performed
using SensiMix dT (Quantace) on a Corbett Rotorgene
3000 and analyzed using Rotor-Gene 6 Version 6.0 (Build
27) (Corbett Research). Primer pairs used for the amplifi-
cation of HMG-CoA reductase from cDNAs are F- ttggtgat-
gggagcttgctgtg; R- agtcacaagcacgtggaagacg. The primer pair
used for amplification of the housekeeping gene PBGD
was described previously [25]. PCR products were verified
by sequencing. The change in gene expression levels was
determined by normalizing mRNA levels of the gene of
interest to the mRNA level of the house-keeping gene, por-
phobilinogen deaminase (PBGD). Melting curve analysis
was performed to confirm production of a single product
in each reaction.
Data Presentation and Statistics
Data are presented as mean + standard error of the means
(SEM) unless otherwise stated. All results are pooled or
representative of at least two separate experiments. Statis-
tical analyses were performed to find correlations (Pear-
son's) between two sets of continuous variables. A P-value
less than 0.05 was considered statistically significant.
Abbreviations
24,25EC, 24(S),25-epoxycholesterol; ABCA1, ATP-bind-
ing cassette transporter-A1; HMG-CoA, 3-hydroxy-3-
methylglutaryl coenzyme A; LXR, liver × receptor; OSC,
2,3-oxidosqualene cyclase; SRE, sterol response element;
SREBP, sterol regulatory element-binding protein; TLC,
thin layer chromatography
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